Does Insurance Cover Wegovy? State-by-State Breakdown

The honest answer to "does insurance cover Wegovy?" is: sometimes, and it depends on who's writing your plan, what state you live in, and whether you have a qualifying medical history. In 2026, roughly 30–35% of commercial plans cover Wegovy for obesity treatment, Medicare generally does not, and Medicaid varies wildly state by state. This guide walks through every major carrier, the typical prior authorization requirements, and a state-by-state Medicaid breakdown.

Wanting a straight answer about *your* plan? Nothing beats the phone. Take the member services number off your insurance card and put the question narrowly: "Is Wegovy on my formulary for obesity treatment? What's the prior authorization requirement?" — formularies change quarterly and your insurer is the only definitive source. For the landscape across major carriers, Medicare, and Medicaid, keep reading.

Key Takeaways

• ~30–35% of commercial plans cover Wegovy for obesity in 2026, usually with prior authorization.
• Medicare Part D does NOT cover Wegovy for weight loss. Limited coverage exists for cardiovascular indication after the 2024 FDA label expansion.
• Medicaid covers Wegovy in roughly 15 states, with strict PA requirements.
• TRICARE covers Wegovy with PA for active-duty, retirees, and dependents meeting BMI criteria.
• Prior authorization nearly always turns on two things: documented prior weight-loss attempts, and BMI at ≥30 — or ≥27 where a comorbidity accompanies it.
• Appeals work. Roughly 40–50% of initial denials are overturned on appeal when the patient meets criteria.

The Big Picture

Commercial insurance coverage for weight-loss medications has grown steadily since Wegovy's 2021 approval, but it's still a minority of plans. A few structural reasons:

1. Employers drive coverage. Most commercial plans are employer-sponsored, and employers have been slow to add GLP-1 obesity coverage because of the cost (a single employee on Wegovy costs ~$12,000/year before rebates).
2. The 2024 cardiovascular indication changed the math. Once SELECT put the reduction in cardiovascular events at 20%, payers began treating "cardiovascular risk reduction" as a different question from "obesity" — and covering them differently.
3. GLP-1 drug rebates are opaque. Pharmacy benefit managers (PBMs) negotiate rebates with Novo Nordisk that can knock 30–50% off list price, but those rebates don't always flow to patients.

For cost specifics if you're covered (or not), see our real cost of Wegovy breakdown.

Major Commercial Carriers

Coverage varies by specific plan within each carrier, but these are the 2026 patterns we see most often:

Blue Cross Blue Shield

BCBS is not one plan — it's a federation of 34 independent companies. Coverage for Wegovy varies dramatically by state. BCBS of Massachusetts, Michigan, and California commercial plans generally cover Wegovy with PA; BCBS of Texas and several Southern states often exclude it. Check your specific plan at blue-cross-blue-shield insurance guide.

UnitedHealthcare

UHC's default commercial formulary excludes Wegovy for weight loss. Individual employers can buy into a "weight management rider" that adds coverage, but the default is no. If your employer offers this rider, you'll see Wegovy on your specific plan's formulary with PA. See UnitedHealthcare insurance guide.

Aetna and Cigna

Both carriers added Wegovy to their standard commercial formularies in 2023–2024 and now cover it for obesity on most plans with PA. Typical PA includes BMI ≥30 or ≥27 with comorbidity, plus documentation of at least 3 months of prior lifestyle intervention. See Aetna insurance guide and Cigna insurance guide.

Medicare: Mostly No

The block on Medicare Part D is statutory. Any drug "when used for anorexia, weight loss, or weight gain" is barred from coverage by the Medicare Modernization Act of 2003. That clause kept phentermine, and the older weight-loss drugs with it, outside Medicare for decades.

The workaround, as of 2024, is the cardiovascular indication. SELECT led the FDA to widen Wegovy's label. Its wording — "reducing the risk of major adverse cardiovascular events" — reaches any adult carrying established cardiovascular disease plus obesity, or plus overweight. On the back of that, CMS told Part D plans they may pay for Wegovy on this indication — while obesity on its own remains outside what they can cover.

In practice: if you have Medicare and a documented history of heart attack, stroke, or established coronary artery disease, you may qualify for Wegovy coverage. Without that cardiovascular history, Medicare Part D won't pay. See Medicare insurance guide for more.

Medicaid: Varies by State

Medicaid coverage for Wegovy is the most complex piece of this picture because each state's Medicaid program sets its own drug formulary. As of late 2025, the rough state-by-state picture:

States Covering Wegovy for Obesity (approximate, as of early 2026)

States NOT Covering Wegovy for Obesity

Most remaining states either exclude GLP-1 drugs for weight management entirely, or cover Ozempic/Mounjaro only for diagnosed type 2 diabetes. This includes Texas, Florida, Georgia, Ohio, Tennessee, Alabama, Arizona, Louisiana, and most of the Mountain West.

This list changes frequently. States add and remove GLP-1 coverage based on Medicaid budget pressures. Verify current status with your state Medicaid program directly. The KFF Medicaid GLP-1 tracker is the best publicly maintained source.

TRICARE

TRICARE covers Wegovy with PA for active-duty service members, retirees, and dependents who meet BMI criteria (≥30 or ≥27 with comorbidity). PA is processed through Express Scripts, the TRICARE pharmacy benefit manager. Typical turnaround is 3–7 days.

Typical Prior Authorization Requirements

Most Wegovy PAs, regardless of carrier, ask for the same documentation:

1. BMI at ≥30 on its own, or ≥27 where a weight-related comorbidity accompanies it
2. Comorbidity documentation where BMI falls in the 27–29.9 band — sleep apnea, dyslipidemia, cardiovascular disease, hypertension or type 2 diabetes
3. A prior weight loss attempt, typically 3–6 months of diet and exercise, evidenced in provider notes
4. Nothing contraindicating — severe GI disease, pancreatitis, MEN-2, or medullary thyroid carcinoma in the patient or the family
5. Reauthorization at 6 or 12 months, carrying documented weight loss of ≥5%

Do's and Don'ts for Getting Approved

Do:

• Start the PA process with complete documentation on day one
• Ask your prescriber's office to include measured BMI and comorbidities in the PA
• Appeal any denial — overturn rates are surprisingly high
• Keep a weight log during your prior lifestyle intervention
• Call your insurer's member services line to verify your formulary before filling — this is the only authoritative source

Don't:

• Assume coverage without verifying — call the number on your insurance card
• Skip the prior lifestyle intervention documentation; this is the #1 denial reason
• Use GoodRx as your primary backup (see Wegovy cost)
• Ignore manufacturer savings cards; they're a better fallback than cash pay

What to Do If You're Denied

1. Request the denial letter in writing with the specific reason.
2. File an appeal within the timeframe specified (usually 60–180 days). Include additional clinical notes, labs, and a letter of medical necessity from your prescriber.
3. External review. If the internal appeal fails, most states allow an independent external review by a third-party reviewer. This is free and binding on the insurer.
4. Explore alternatives. If appeals fail, the Novo Nordisk savings card drops the cost to $499/month for commercially insured patients. See manufacturer coupons or compounded semaglutide options in our best providers ranking.

Bottom Line

Insurance coverage for Wegovy in 2026 is a minority outcome, not a default. Roughly one in three commercially insured patients will get coverage with prior authorization; the rest will pay out of pocket or switch to compounded semaglutide. Medicare and Medicaid coverage is limited and state-dependent. One action beats every other: check the formulary before you commit to any treatment path. The number is on your insurance card, and the question to ask is whether Wegovy is covered for obesity.

If you're not covered, don't give up: the Novo Nordisk savings card, compounded semaglutide through a trusted telehealth provider, and an appeal of an initial denial all remain viable paths. For the full pricing picture across every scenario, see our real cost of Wegovy guide.